Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 7/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287257 | 1.00 | KCNJ1 (0.35) | KCNJ1PDE10ADRD4OPRM1LMNA | |
| SCHEMBL25193039 | 1.00 | KCNJ1 (0.35) | KCNJ1PDE10ADRD4OPRM1LMNA | |
| SCHEMBL23924996 | 0.91 | KCNJ1 (0.36) | KCNJ1PDE10ADRD4OPRM1MEN1 | |
| SCHEMBL30287196 | 0.91 | KCNJ1 (0.36) | KCNJ1PDE10ADRD4OPRM1MEN1 | |
| SCHEMBL25264680 | 0.91 | KCNJ1 (0.36) | KCNJ1PDE10ADRD4OPRM1MEN1 | |
| SCHEMBL30287140 | 0.86 | KCNJ1 (0.32) | KCNJ1 | |
| SCHEMBL30287279 | 0.84 | MEN1 (0.39) | KCNJ1DRD4LMNAMAPK1MEN1 | |
| SCHEMBL25200844 | 0.84 | MEN1 (0.39) | KCNJ1DRD4LMNAMAPK1MEN1 | |
| SCHEMBL25200846 | 0.84 | MEN1 (0.39) | KCNJ1DRD4LMNAMAPK1MEN1 | |
| SCHEMBL23925078 | 0.84 | KCNJ1 (0.35) | KCNJ1DRD4OPRM1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | KCNJ1 3562/4885PDE10A 2768/4885DRD4 4343/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | KCNJ1 3562/4885PDE10A 2768/4885DRD4 4343/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | KCNJ1 3562/4885PDE10A 2768/4885DRD4 4343/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | KCNJ1 3562/4885PDE10A 2768/4885DRD4 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.